Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical stage biotechnology company developing immune-modulating therapies centered on the CD40 Ligand (CD40L) pathway. The company’s news flow largely reflects progress with its lead investigational product, tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand that Eledon describes as having broad therapeutic potential.
News updates for ELDN commonly cover clinical trial milestones in kidney allograft transplantation, islet cell transplantation, xenotransplantation and amyotrophic lateral sclerosis (ALS). For example, Eledon has issued press releases on Phase 2 BESTOW trial results in de novo kidney transplant recipients, highlighting kidney function outcomes, safety and tolerability compared with tacrolimus-based regimens. Additional announcements have detailed updated data from a Phase 1b open-label kidney transplant study and long-term extension work.
Another recurring theme in Eledon’s news is the use of tegoprubart in islet transplantation for individuals with type 1 diabetes. The company has reported preliminary results from an investigator-initiated trial at the University of Chicago Medicine’s Transplant Institute, describing insulin independence and improved glycemic control in the first treated subjects. Eledon also issues updates on tegoprubart’s role in xenotransplantation, including its use as a key component of immunosuppression regimens in pig-to-human kidney transplant procedures at Massachusetts General Hospital.
Investors following ELDN news can also expect announcements related to scientific conference presentations, participation in healthcare conferences, financing transactions such as underwritten public offerings of common stock and pre-funded warrants, and selected financial results. This news page aggregates such disclosures so readers can review Eledon’s reported clinical data, corporate developments and regulatory-related communications over time.
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on autoimmune diseases and organ transplants, announced an upcoming presentation on its lead candidate AT-1501 at the IPITA Congress, taking place virtually from October 20-23, 2021. The oral presentation, titled Use of Novel Antibodies/Mechanisms for Achieving Islet Transplantation Tolerance, will showcase pre-clinical data on AT-1501's effectiveness in preventing islet allograft rejection in nonhuman primate models. The session is scheduled for October 22 at 9:50 AM EST.
Eledon Pharmaceuticals (ELDN), a clinical stage biopharmaceutical company, announced upcoming presentations at major healthcare conferences. Management will present on-demand at the HC Wainwright 23rd Annual Global Investment Conference starting on September 13, 2021, at 7:00 AM EST. Additionally, a corporate overview will be presented at the Cantor Global Healthcare Conference on September 30, 2021, at 3:20 PM EST. The presentations can be accessed for 90 days post-event on the company's website. Eledon focuses on developing targeted medicines for patients with autoimmune diseases and ALS.
Eledon Pharmaceuticals announced significant progress in developing AT-1501 for kidney transplantation, receiving a No Objection Letter from Health Canada to initiate a clinical trial and agreeing with the FDA on a preclinical study involving non-human primates. The company also plans to develop AT-1501 for IgA nephropathy, with a Phase 2 trial set to begin by the end of 2021. Financially, Eledon reported a net loss of $7.4 million for Q2 2021, up from a loss of $2.6 million the previous year, with a cash balance of $101.1 million.
Eledon Pharmaceuticals (NASDAQ: ELDN) will report its financial results for Q2 2021 on August 12, after market close. A conference call and webcast will be held at 4:30 PM ET the same day. Eledon focuses on developing targeted therapies for autoimmune diseases and conditions requiring organ transplants, as well as ALS. Its lead candidate, AT-1501, targets the CD40L pathway, which has shown promise in improving treatment safety and efficacy. More information can be found on Eledon's website.
Eledon Pharmaceuticals (NASDAQ: ELDN) has received a No Objection Letter from Health Canada for its clinical trial application of AT-1501, intended to replace tacrolimus in kidney transplant patients. This multicenter, open-label study will involve 6 to 12 subjects to assess AT-1501’s safety, efficacy, and pharmacokinetics. Interim data is expected in late 2022. According to CEO David-Alexandre Gros, this study aims to potentially improve transplant outcomes and decrease side effects associated with current immunosuppressive therapies.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced the appointment of Dr. Jan Hillson to its Board of Directors. Dr. Hillson is the Senior VP of Clinical Development at Alpine Immune Sciences and brings extensive experience in immunology and rheumatology. CEO David-Alexandre Gros expressed confidence that her insights will be valuable in advancing Eledon's lead drug, AT-1501, through clinical development. AT-1501 is designed to treat autoimmune diseases, organ transplants, and ALS. The company is focused on targeting the CD40L pathway for therapeutic benefits.
Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical-stage biopharmaceutical company, announced a corporate presentation at the Ladenburg Thalmann Healthcare Conference on July 13 at 2:00 pm EST. The company focuses on developing treatments targeting autoimmune diseases, organ transplant requirements, and ALS. Its lead compound, AT-1501, is an anti-CD40L antibody designed to enhance efficacy and safety by inhibiting CD40L, thus regulating immune responses. A replay of the presentation will be available for 30 days post-event on the company’s website.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a biopharmaceutical firm focused on autoimmune diseases and organ transplant treatments, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30pm EST. Interested participants can register here.
A replay will be available for 30 days on the company’s website. Eledon is developing AT-1501, an anti-CD40L antibody, for autoimmune diseases and transplants, aiming for improved safety and efficacy.
Eledon Pharmaceuticals reported its Q1 2021 financial results, highlighting continued enrollment in the Phase 2 trial of AT-1501 for ALS, with top line data expected in H1 2022. The company appointed four key executives, enhancing its leadership team. Q1 net loss was $8.5 million, or $0.57 per share, up from $8.2 million, or $8.52 per share, year-over-year. R&D expenses surged to $5.6 million, compared to $1.6 million in 2020. Eledon has $108.6 million in cash, ensuring operational funding into 2023. Upcoming milestones include initiating additional trials and presenting data at the American Society of Transplantation conference.
Eledon Pharmaceuticals, a clinical-stage biopharmaceutical company, announced presentations for its lead product candidate, AT-1501, at the American Transplant Congress (ATC) from June 4-9, 2021. The presentations include Phase 1 data on AT-1501's safety, tolerability, and pharmacokinetics, alongside pre-clinical data demonstrating its effectiveness in preventing islet allograft rejection in nonhuman primates. Two additional posters will cover pharmacokinetics, toxicity, and characterization of AT-1501. More information is available on the ATC website.